Topics

Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies

01:30 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
5 novel oncolytic immunotherapies will be developed based on Transgene’s new Invir.IOTM platform Transgene to receive $10 million upon signing and is eligible to receive further development mileston...

Other Sources for this Article

Transgene:
Lucie Larguier
+33 (0)3 88 27 91 21
investorrelations@transgene.fr

Media: Citigate Dewe Rogerson
EU: David Dible/Sylvie Berrebi
US: Marine Perrier-Barthez
+ 44 (0)20 7638 9571 / +1 424 341 9140
transgene@citigatedewerogerson.com

NEXT ARTICLE

More From BioPortfolio on "Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...